Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
about
Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.Current and future therapies for treating chronic spontaneous urticaria.Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies.
P2860
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@ast
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@en
type
label
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@ast
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@en
prefLabel
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@ast
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@en
P2093
P1476
Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
@en
P2093
Daniel Har
David A Khan
Saurin Patel
P304
P356
10.1016/J.ANAI.2015.05.010
P577
2015-06-17T00:00:00Z